Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic ren2 rats

American Journal of Pathology

Volumn 174, Issue 4, 2009, Pages 1329-1337

  Wei, Yongzhong ^a,b   Clark, Suzanne E ^a,b   Thyfault, John P ^a,b   Uptergrove, Grace M E ^a,b   Li, Wenhan ^a,b   Whaley Connell, Adam T ^a,b   Ferrario, Carlos M ^c   Sowers, James R ^a,b   Ibdah, Jamal A ^a,b  

^a University of Missouri   (United States)

^b WJB Dorn VA Medical Center   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ACETYL COENZYME A CARBOXYLASE; ANGIOTENSIN II; CARBON DIOXIDE; CATALASE; CITRATE SYNTHASE; CYTOCHROME C; CYTOCHROME C OXIDASE; FAS ANTIGEN; PALMITIC ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; TEMPOL; VALSARTAN; AMINE OXIDE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; DRUG DERIVATIVE; FATTY ACID; MITOCHONDRIAL DNA; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; GENE EXPRESSION; LIPID PEROXIDATION; LIVER; MALE; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TRANSGENIC RAT; ANIMAL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPIN LABELING; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; CYCLIC N-OXIDES; DNA, MITOCHONDRIAL; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPIN LABELS; TETRAZOLES; VALINE;

EID: 65349125289     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080697     Document Type: Article

References (42)

1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231
2. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649-1657
3. Rector RS, Thyfault JP, Wei Y, Ibdah JA: Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008, 14:185-192
4. Wei Y, Rector RS, Thyfault JP, Ibdah JA: Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008, 14:193-199
5. Monto A: Hepatitis C and steatosis. Semin Gastrointest Dis 2002, 13:40-46
6. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J: Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002, 37:154-160
7. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017
8. Sowers JR: Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002, 346:1999-2001
9. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, Colmenero J, Nicolas JM, Jimenez W, Weich N, Gutierrez-Ramos JC, Arroyo V, Rodes J: Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003, 125:117-125
10. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA: Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol 2003, 285:G642-G651
11. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ: Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000, 118:565-572
12. Kurita S, Takamura T, Ota T, Matsuzawa-Nagata N, Kita Y, Uno M, Nabemoto S, Ishikura K, Misu H, Ando H, Zen Y, Nakanuma Y, Kaneko S: Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Eur J Pharmacol 2008, 588:316-324
13. Munoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE: Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 2006, 24:1607-1617
14. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833
15. Ran J, Hirano T, Adachi M: Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol 2004, 287:E227-E232
16. Ran J, Hirano T, Adachi M: Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol 2004, 287:E955-E961
17. Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R: ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008, 16:770-776
18. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA: Angiotensin II-in- duced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008, 49: 417-428
19. de Cavanagh EM, Inserra F, Ferder M, Ferder L: From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 2007, 27:545-553
20. Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW, Ibdah JA: Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol 2008, 294:G619-G626
21. Diehl AM: Fatty liver, hypertension, and the metabolic syndrome. Gut 2004, 53:923-924
22. Brookes MJ, Cooper BT: Hypertension and fatty liver: guilty by association? J Hum Hypertens 2007, 21:264-270
23. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004, 53:1020-1023
24. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS: Mice lacking angiotensin-con- verting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008, 105:6531-6536
25. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL: PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin Il-infused rats. J Mol Cell Cardiol 2004, 36:295-304
26. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002, 40:872-879
27. Caldwell SH, Swerdlow RH, Khan EM, lezzoni JC, Hespenheide EE, Parks JK, Parker Jr WD: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999, 31:430-434
28. Reddy JK, Rao MS: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol 2006, 290: G852-G858
29. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192
30. Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, Wagner JD, Matern D, Rinaldo P, Cline JM: Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005, 128:1381-1390
31. Li H, Wang J, Wilhelmsson H, Hansson A, Thoren P, Duffy J, Rustin P, Larsson NG: Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci USA 2000, 97:3467-3472
32. Croteau DL, Stierum RH, Bohr VA: Mitochondrial DNA repair pathways. Mutat Res 1999, 434:137-148
33. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Letteron P, Degott C, Feldmann G, Pessayre D, Fromenty B: Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002, 123:1278-1290
34. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM: The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. FEBS Lett 2000, 466:323-326
35. Chen J, Schenker S, Frosto TA, Henderson GI: Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta 1998, 1380:336-344
36. Chen J, Petersen DR, Schenker S, Henderson GI: Formation of mal- ondialdehyde adducts in livers of rats exposed to ethanol: role in ethanol-mediated inhibition of cytochrome c oxidase. Alcohol Clin Exp Res 2000, 24:544-552
37. Doughan AK, Harrison DG, Dikalov SI: Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochon- drial oxidative damage and vascular endothelial dysfunction. Circ Res 2008, 102:488-496
38. Muller FL, Liu Y, Van RH: Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 2004, 279:49064-49073
39. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT: Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 2005, 280:42026-42035
40. Han Z, Chen YR, Jones III CI, Meenakshisundaram G, Zweier JL, Alevriadou BR: Shear-induced reactive nitrogen species inhibit mitochondrial respiratory complex activities in cultured vascular endothelial cells. Am J Physiol 2007, 292:C1103-C1112
41. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C: Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006, 55:2159-2170
42. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131